<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37326693</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Agomir miRNA-150-5p alleviates pristane-induced lupus by suppressing myeloid dendritic cells activation and inflammation via TREM-1 axis.</ArticleTitle><Pagination><StartPage>1391</StartPage><EndPage>1408</EndPage><MedlinePgn>1391-1408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-023-01754-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Triggering receptors expressed on myeloid cells-1 (TREM-1) has been shown to participate in inflammatory autoimmune diseases. Nevertheless, the detailed underlying mechanisms and therapeutic benefits by targeting TREM-1 remain elusive, especially in myeloid dendritic cells (mDCs) and systemic lupus erythematosus (SLE). Disorders of epigenetic processes including non-coding RNAs give rise to SLE, resulting in complicated syndromes. Here, we aim to address this issue and explore the miRNA to inhibit the activation of mDCs and alleviate the progress of SLE by targeting TREM-1 signal axis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Bioinformatics methods were used to analyze the differentially expressed genes (DEGs) between patients with SLE and healthy individuals by four mRNA microarray datasets from Gene Expression Omnibus (GEO). Then we identified the expression of TREM-1 and its soluble form (sTREM-1) in clinical samples by ELISA, quantitative real-time PCR and Western blot. Phenotypic and functional changes of mDCs elicited by TREM-1 agonist were determined. Three databases of miRNAs target prediction and a dual-luciferase reporter assay were used to screen and verify miRNAs that can directly inhibit TREM-1 expression in vitro. Moreover, pristane-induced lupus mice were injected with miR-150-5p agomir to evaluate the effects of miR-150-5p on mDCs in lymphatic organs and disease activity in vivo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We screened TREM-1 as one of the hub genes closely correlated with the progression of SLE and identified sTREM-1 in serum as a valuable diagnostic biomarker for SLE. Moreover, activation of TREM-1 by its agonist promoted activation and chemotaxis of mDCs and increased the production of inflammatory cytokines and chemokines, showing higher expression of IL-6, TNF-&#x3b1;, and MCP-1. We showed that lupus mice displayed a unique miRNA signature in spleen, among which miR-150 was the most significantly expressed miRNA that targeting TREM-1 compared with wild type group. Transfection of miRNA-150-5p mimics directly suppressed the expression of TREM-1 by binding to its 3' UTR. Our in vivo experiments first indicated that administration of miR-150-5p agomir effectively ameliorated lupus symptoms. Intriguingly, miR-150 inhibited the over activation of mDCs through TREM-1 signal pathway in lymphatic organs and renal tissues.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TREM-1 represents a potentially novel therapeutic target and we identify miR-150-5p as one of the mechanisms to alleviate lupus disease, which is attributable for inhibiting mDCs activation through TREM-1 signaling pathway.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yue</LastName><ForeName>Chenran</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Wenqian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Plastic Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gao</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory Animal Center, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ye</LastName><ForeName>Jianzhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Zhouhang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Hengrong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of the 2Nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xueyin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of the 2Nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuting</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of the 2Nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Anni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of the 2Nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liangxing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Heart and Lung, Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China. wangliangxing@wzhospital.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianguang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China. wz_wjg@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China. huachunyan@wmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Y20220045</GrantID><Agency>Science and Technology Plan Project of Wenzhou</Agency><Country/></Grant><Grant><GrantID>Y20220389</GrantID><Agency>Science and Technology Plan Project of Wenzhou</Agency><Country/></Grant><Grant><GrantID>81901660</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>LTGY23H100001</GrantID><Agency>Zhejiang Province Natural Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073871">Triggering Receptor Expressed on Myeloid Cells-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>26HZV48DT1</RegistryNumber><NameOfSubstance UI="C009042">pristane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073871" MajorTopicYN="N">Triggering Receptor Expressed on Myeloid Cells-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">TREM-1 signaling pathway</Keyword><Keyword MajorTopicYN="N">mDCs</Keyword><Keyword MajorTopicYN="N">miR-150-5p</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37326693</ArticleId><ArticleId IdType="doi">10.1007/s00011-023-01754-8</ArticleId><ArticleId IdType="pii">10.1007/s00011-023-01754-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med 2020; 172:ITC81-ITC96.</Citation></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393:2332&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26:502&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25014039</ArticleId><ArticleId IdType="pmc">4221732</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000089</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019;15:403&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31165780</ArticleId><ArticleId IdType="doi">10.1038/s41584-019-0235-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F, Franc&#xe8;s C. Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive review. Drugs. 2019;79:1199&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">31228033</ArticleId><ArticleId IdType="doi">10.1007/s40265-019-01151-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A, M&#xfc;ller F, Mougiakakos D, B&#xf6;ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">36109639</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Chen C, Wu Z, Zhang W, Wang L, Yu J, et al. Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus. Biomaterials. 2022;285: 121517.</Citation><ArticleIdList><ArticleId IdType="pubmed">35504179</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121517</ArticleId></ArticleIdList></Reference><Reference><Citation>Szelinski F, Lino AC, D&#xf6;rner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34:125&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">34939607</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutertre C-A, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 2019; 51.</Citation></Reference><Reference><Citation>Xiao ZX, Hu X, Zhang X, Chen Z, Wang J, Jin K, et al. High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways. Signal Transduct Target Ther. 2020;5:34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32296043</ArticleId><ArticleId IdType="pmc">7145808</ArticleId><ArticleId IdType="doi">10.1038/s41392-020-0139-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhang X, Cao X. Dendritic cells in systemic lupus erythematosus: from pathogenesis to therapeutic applications. J Autoimmun. 2022;132: 102856.</Citation><ArticleIdList><ArticleId IdType="pubmed">35773101</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2022.102856</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n JC, Vargas-Rojas MI, Monsiv&#xe1;is-Urenda A, Alcocer-Varela J. Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. Clin Immunol. 2012;143:45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">22239954</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2011.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleisner MA, Reyes P, Alfaro J, Solanes P, Simon V, Crisostomo N, et al. Dendritic and stromal cells from the spleen of lupic mice present phenotypic and functional abnormalities. Mol Immunol. 2013;54:423&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23428837</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2013.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Gong Y, Ji J, Yuan L, Han L, Guo Y, et al. A new benzenediamine derivative modulates Toll-like receptors-induced myeloid dendritic cells activation and ameliorates lupus-like syndrome in MRLlpr/lpr mice. Eur J Pharmacol 2017; 803.</Citation></Reference><Reference><Citation>Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110943</ArticleId><ArticleId IdType="doi">10.1038/ni1411</ArticleId></ArticleIdList></Reference><Reference><Citation>Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013;19:623&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23475790</ArticleId><ArticleId IdType="doi">10.1177/1753425913476970</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Pi&#xf1;a V, Soares-Schanoski A, Rodr&#xed;guez-Rojas A, Del Fresno C, Garc&#xed;a F, Vallejo-Cremades MT, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol. 2007;179:4065&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785845</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.179.6.4065</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras M-C, Lapillonne H, Margolin JF. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol. 2002;38:817&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922939</ArticleId><ArticleId IdType="doi">10.1016/S0161-5890(02)00004-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care. 2012;27:294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">21855288</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2011.06.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibot S, Cravoisy A, Levy B, Bene M-C, Faure G, Bollaert P-E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14749453</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa031544</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi ST, Kang E-J, Ha YJ, Song J-S. Levels of plasma-soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) are correlated with disease activity in rheumatoid arthritis. J Rheumatol. 2012;39:933&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22422501</ArticleId><ArticleId IdType="doi">10.3899/jrheum.111218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Brooks JD. Gene expression changes induced by unilateral ureteral obstruction in mice. J Urol. 2012;188:1033&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22819101</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2012.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012;72:3977&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">22719066</ArticleId><ArticleId IdType="pmc">3694446</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-0938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelham CJ, Pandya AN, Agrawal DK. Triggering receptor expressed on myeloid cells receptor family modulators: a patent review. Expert Opin Ther Pat. 2014;24:1383&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25363248</ArticleId><ArticleId IdType="pmc">4596234</ArticleId><ArticleId IdType="doi">10.1517/13543776.2014.977865</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning N-L, Aziz M, Murao A, Gurien SD, Ochani M, Prince JM, et al. Extracellular CIRP as an endogenous TREM-1 ligand to fuel inflammation in sepsis. JCI Insight 2020; 5.</Citation></Reference><Reference><Citation>Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799849</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.164.10.4991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Lefebvre AT, Ajith A, Portik-Dobos V, Horuzsko DD, Arbab AS, Dzutsev A, et al. The innate immune receptor TREM-1 promotes liver injury and fibrosis. J Clin Invest. 2018;128:4870&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30137027</ArticleId><ArticleId IdType="pmc">6205377</ArticleId><ArticleId IdType="doi">10.1172/JCI98156</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffre J, Potteaux S, Zeboudj L, Loyer X, Boufenzer A, Laurans L, et al. Genetic and pharmacological inhibition of TREM-1 limits the development of experimental atherosclerosis. J Am Coll Cardiol. 2016;68:2776&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">28007141</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2016.10.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70:198&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">30810243</ArticleId><ArticleId IdType="doi">10.1002/hep.30593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Yi Y, Xia G, Yu C, Ye C, Tu F, et al. The characteristics and pivotal roles of triggering receptor expressed on myeloid cells-1 in autoimmune diseases. Autoimmun Rev. 2019;18:25&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">30408584</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2018.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323674</ArticleId><ArticleId IdType="doi">10.1038/35074114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaro A, Derive M, Gibot S, Leemans JC, Florquin S, Dessing MC. TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives. Pharmacol Ther. 2017;177:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">28245991</ArticleId><ArticleId IdType="doi">10.1016/j.pharmthera.2017.02.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandupuspitasari NS, Khan FA, Huang C-J, Chen X, Zhang S. Novel attributions of TREMs in immunity. Curr Issues Mol Biol. 2016;20:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26738206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Yuan L, Wang Y, Hua C. Enhanced expression of TREM-1 in splenic cDCs in lupus prone mice and it was modulated by miRNA-150. Mol Immunol. 2017;81:127&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">27940256</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2016.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R-Y, Yu Y-L, Cheng W-C, OuYang C-N, Fu E, Chu C-L. Immunosuppressive effect of quercetin on dendritic cell activation and function. J Immunol. 2010;184:6815&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483746</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0903991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M, Xu C, Zhang Q, Wu X, Tang L, Wang X, et al. Inhibition of p21-activated kinase 1 attenuates the cardinal features of asthma through suppressing the lymph node homing of dendritic cells. Biochem Pharmacol. 2018;154:464&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">29906467</ArticleId><ArticleId IdType="doi">10.1016/j.bcp.2018.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding C, Chen X, Dascani P, Hu X, Bolli R, Zhang H-G, et al. STAT3 signaling in b cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus. J Immunol. 2016;196:4477&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27183592</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1502043</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L, Tang X, Zhou K, Wang D, Wang S, Yao G, et al. MicroRNA-663 induces immune dysregulation by inhibiting TGF-&#x3b2;1 production in bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Cell Mol Immunol. 2019;16:260&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">30886422</ArticleId><ArticleId IdType="doi">10.1038/cmi.2018.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qi Y, Xu W-H, Liu Y, Qiu L, Wang K-Q, et al. Matrine derivate MASM suppresses LPS-induced phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int Immunopharmacol. 2016;36:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">27107799</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2016.04.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva MT, et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat Immunol. 2018;19:571&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29760532</ArticleId><ArticleId IdType="pmc">5976527</ArticleId><ArticleId IdType="doi">10.1038/s41590-018-0107-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas CA, Tejwani L, Trujillo CA, Negraes PD, Herai RH, Mesci P, et al. Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. Cell Stem Cell 2017; 21.</Citation></Reference><Reference><Citation>Cavaillon J-M. Monocyte TREM-1 membrane expression in non-infectious inflammation. Crit Care. 2009;13:152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519945</ArticleId><ArticleId IdType="pmc">2717434</ArticleId><ArticleId IdType="doi">10.1186/cc7882</ArticleId></ArticleIdList></Reference><Reference><Citation>Molad Y, Pokroy-Shapira E, Kaptzan T, Monselise A, Shalita-Chesner M, Monselise Y. Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection. Inflammation. 2013;36:1519&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23872722</ArticleId><ArticleId IdType="doi">10.1007/s10753-013-9694-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassyouni IH, Fawzi S, Gheita TA, Bassyouni RH, Nasr AS, El Bakry SA, et al. Clinical association of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in patients with systemic lupus erythematosus. Immunol Invest. 2017;46:38&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">27648678</ArticleId><ArticleId IdType="doi">10.1080/08820139.2016.1211140</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-J, Tsai C-Y, Chiang S-H, Tang S-J, Chen N-J, Mak TW, et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) deficiency augments BAFF production to promote lupus progression. J Autoimmun 2017; 78.</Citation></Reference><Reference><Citation>Haselmayer P, Grosse-Hovest L, von Landenberg P, Schild H, Radsak MP. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood. 2007;110:1029&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452516</ArticleId><ArticleId IdType="doi">10.1182/blood-2007-01-069195</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11711679</ArticleId><ArticleId IdType="doi">10.1126/science.1064890</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12604793</ArticleId><ArticleId IdType="pmc">151388</ArticleId><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan VS-F, Nie Y-J, Shen N, Yan S, Mok M-Y, Lau C-S. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 2012; 11:890&#x2013;897.</Citation></Reference><Reference><Citation>Hong S-M, Liu C, Yin Z, Wu L, Qu B, Shen N. MicroRNAs in systemic lupus erythematosus: a perspective on the path from biological discoveries to clinical practice. Curr Rheumatol Rep. 2020;22:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">32405712</ArticleId><ArticleId IdType="doi">10.1007/s11926-020-00895-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wu H, Zhao M, Chang C, Lu Q. Clinical significance of miRNAs in autoimmunity. J Autoimmun. 2020;109: 102438.</Citation><ArticleIdList><ArticleId IdType="pubmed">32184036</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2020.102438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Song Y, Du P, Yang S, Cui H, Lu S, et al. Administration of a microRNA-21 inhibitor improves the lupus-like phenotype in MRL/lpr mice by repressing Tfh cell-mediated autoimmune responses. Int Immunopharmacol. 2022;106: 108578.</Citation><ArticleIdList><ArticleId IdType="pubmed">35124415</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2022.108578</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H, Cao Q, Liu Q. MicroRNA-16 directly binds to DEC2 and inactivates the TLR4 signaling pathway to inhibit lupus nephritis-induced kidney tissue hyperplasia and mesangial cell proliferation. Int Immunopharmacol. 2020;88: 106859.</Citation><ArticleIdList><ArticleId IdType="pubmed">32795896</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2020.106859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng T, Ding S, Liu S, Li Y, Sun L. Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis. Theranostics. 2021;11:893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">33391511</ArticleId><ArticleId IdType="pmc">7738872</ArticleId><ArticleId IdType="doi">10.7150/thno.48080</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>